Summary
This study addresses the hypothesis that intermittent treatment with fenretinide intravenous
emulsion will induce objective responses in patients with relapsed or refractory Peripheral
T-cell Lymphoma (PTCL) who have failed at least one prior systemic therapy and will result in
acceptable toxicities.